Jane Buckner, MD
Director, Translational Sample Core
Dr. Buckner received her bachelor’s degree in chemistry from Carleton College, magna cum laude. She attended Johns Hopkins School of Medicine, and after receiving her MD, she completed her residency training in Internal Medicine at the University of Minnesota. Dr. Buckner went on to complete a fellowship in rheumatology at the University of Washington. As a fellow she was honored with the American College of Rheumatology’s Senior Rheumatology Scholar Award. After completing her medical training, Dr. Buckner continued her research training as a postdoctoral fellow in the laboratory of Dr. Gerald Nepom. In 1999, she was the recipient of the ACR Arthritis Investigator Award. Since 1999, Dr. Buckner has been an investigator at the Benaroya Research Institute (BRI). She became the Director of the Translational Research Program at BRI in 2005, was named Associate Director of BRI in January 2012 and was appointed President of BRI in January 2016.
Dr. Buckner continues to care for rheumatology patients at the Virginia Mason Medical Center, and she is an affiliate professor of medicine in the Division of Rheumatology at the University of Washington, an affiliate professor of immunology in the UW School of Medicine, an affiliate of the UW Diabetes Research Center, an active member of the Type 1 Diabetes TrialNet Biomarker and Mechanisms Panel, and a member of the Brehm Coalition.
Area of Research
Dr. Buckner’s laboratory is focused on identifying the underlying mechanisms by which regulation of the adaptive immune response fails or is overcome in the setting of human autoimmunity. The diseases studied in Dr. Buckner’s laboratory include type 1 diabetes (T1D), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and relapsing polychondritis. Her laboratory is currently examining the question of how autoreactive T and B cells escape regulation in these diseases and the closely related question of whether the development or function of regulatory T cells is impaired in autoimmunity. Her group uses the genetics of autoimmunity to identify pathways that contribute to the failure of tolerance in these diseases.
Through BRI’s commitment to groundbreaking research, Dr. Buckner serves as a principal investigator (PI) in a new partnership with the Allen Institute for Immunology, profiling healthy immune systems to serve as a foundation for existing and future disease research programs. She is also a PI in a new collaborative research effort with the Parker Institute for Cancer Immunotherapy, JDRF and The Leona M. and Harry B. Helmsley Charitable Trust to understand, predict and prevent insulin-dependent diabetes following checkpoint therapy for cancer. In addition, Dr. Buckner founded and oversees BRI’s large biorepository, which collects biological samples from both healthy individuals and individuals with autoimmune diseases and serves as an invaluable resource for scientists to accelerate their understanding of human autoimmune disease.Dr. Buckner's CV
Lord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, Kita M, Buckner JH. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Clin Immunol. 2018 Aug;193:24-32.
Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA.
Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes. 2018 Jul;67(7):1216-1225.
Buckner JH, Greenbaum CJ. Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease. J Immunol. 2017 Nov 1;199(9):3011-3013.
Eken A, Duhen R, Singh AK, Fry M, Buckner JH, Kita M, Bettelli E, Oukka M. S1P1 deletion differentially affects TH17 and Regulatory T cells. Sci Rep. 2017 Oct 10;7(1):12905. PMC5635040
Arkatkar T, Du SW, Jacobs HM, Dam EM, Hou B, Buckner JH, Rawlings DJ, Jackson SW. B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity. J Exp Med. 2017 Nov 6;214(11):3207-3217. PMC5679179
Metzler G, Dai X, Thouvenel CD, Khim S, Habib T, Buckner JH, Rawlings DJ. The Autoimmune Risk Variant PTPN22 C1858T Alters B Cell Tolerance at Discrete Checkpoints and Differentially Shapes the Naive Repertoire. J Immunol. 2017 Oct 1;199(7):2249-2260.
Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M. Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. 2017 Nov;60(11):2139-2147. PMC5838353
Carmona-Rivera C, Carlucci PM, Moore E, Lingampalli N, Uchtenhagen H, James E, Liu Y, Bicker KL, Wahamaa H, Hoffmann V, Catrina AI, Thompson P, Buckner JH, Robinson WH, Fox DA, Kaplan MJ. Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. Sci Immunol. 2017 Apr;2(10). pii: eaag3358. PMC5479641
Long AE, Tatum M, Mikacenic C, Buckner JH. A novel and rapid method to quantify Treg mediated suppression of CD4 T cells. J Immunol Methods. 2017 Oct;449:15-22.
Schwedhelm K, Thorpe J, Murray SA, Gavin M, Speake C, Greenbaum C, Cerosaletti K, Buckner J, Long SA.Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state. Clin Immunol. 2017 Aug;181:67-74. PMC5564451
Gorman JA, Hundhausen C, Errett JS, Stone AE, Allenspach EJ, Ge Y, Arkatkar T, Clough C, Dai X, Khim S, Pestal K, Liggitt D, Cerosaletti K, Stetson DB, James RG, Oukka M, Concannon P, Gale M Jr, Buckner JH, Rawlings DJ. The A946T variant of the RNA sensor IFIH1 mediates an interferon program that limits viral infection but increases the risk for autoimmunity. Nat Immunol. 2017 Jul;18(7):744-752. PMC5697900
Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C, Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group. Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2881-2886. PMC5546870
Gerstner C, Dubnovitsky A, Sandin C, Kozhukh G, Uchtenhagen H, James EA, Rönnelid J, Ytterberg AJ, Pieper J, Reed E, Tandre C, Rieck M, Zubarev RA, Rönnblom L, Sandalova T, Buckner JH, Achour A, Malmström V. Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted α-Enolase T Cell Epitope in Rheumatoid Arthritis. Front Immunol. 2016 Nov 14;7:494. PMC5108039
Dam EM, Habib T, Chen J, Funk A, Glukhova V, Davis-Pickett M, Wei S, James R, Buckner JH, Cerosaletti K. (2016) The BANK1 SLE-risk variants are associated with alterations in peripheral B cell signaling and development in humans.Clin Immunol. 2016 Dec;173:171-180. PMC5148640
Hundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, Wight TN, Greenbaum CJ, Cerosaletti K, Buckner JH. (2016) Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci Transl Med. 8(356):356ra119. PMC5125295
Johnson MC, Pierson ER, Spieker AJ, Nielsen AS, Posso S, Kita M, Buckner JH, Goverman JM. (2016) Distinct T cell signatures define subsets of patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 3(5):e278. PMC4996538
Uchtenhagen H, Rims C, Blahnik G, Chow IT, Kwok WW, Buckner JH, James EA.(2016) Efficient ex vivo analysis of CD4+ T-cell responses using combinatorial HLA class II tetramer staining. Nat Commun. 7:12614. PMC5013714
Jackson SW, Jacobs HM, Arkatkar T, Dam EM, Scharping NE, Kolhatkar NS, Hou B, Buckner JH, Rawlings DJ.(2016) B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J Exp Med. 213(5):733-50. PMC4854732
Buckner JH, Nepom GT. (2016) Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes. J Autoimmun. 2016 Jul;71:44-50. PMC4903876
Sparks JA, Chang SC, Deane KD, Gan RW, Kristen Demoruelle M, Feser ML, Moss L, Buckner JH, Keating RM, Costenbader KH, Gregersen PK, Weisman MH, Mikuls TR, O'Dell JR, Michael Holers V, Norris JM, Karlson EW. (2016) Associations of Smoking and Age With Inflammatory Joint Signs Among Unaffected First-Degree Relatives of Rheumatoid Arthritis Patients: Results From Studies of the Etiology of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Aug;68(8):1828-38. PMCID In Process
Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF. (2016) CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 196:2051-62. PMC4761490
Hamerman JA, Pottle J, Ni M, He Y, Zhang ZY, Buckner JH. (2016) Negative regulation of TLR signaling in myeloid cells-implications for autoimmune diseases. Immunol Rev. 269:212-27. PMC4703580
Ge Y, Onengut-Gumuscu S, Quinlan AR, Mackey AJ, Wright JA, Buckner JH, Habib T, Rich SS, Concannon P. (2016) Targeted Deep Sequencing in Multiple-Affected Sibships of European Ancestry Identifies Rare Deleterious Variants in PTPN22 That Confer Risk for Type 1 Diabetes. Diabetes. 65:794-802. PMC4764149
Gan RW, Young KA, Zerbe GO, Demoruelle MK, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Clare-Salzler MJ, Deane KD, Holers VM, Norris JM. (2016) Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis: a nested case-control study. Rheumatology (Oxford). 55:367-76. PMC5009416
Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. (2015) Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 7:315ra189. PMC4729454
Rawlings DJ, Dai X, Buckner JH. (2015) The role of PTPN22 risk variant in the development of autoimmunity: finding common ground between mouse and human. J Immunol. 194:2977-84. PMC4369788
Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D. (2015) Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 58:48-58.
Mikacenic C, Schneider A, Radella F, Buckner JH, Wurfel MM. (2014) Cutting edge: Genetic variation in TLR1 is associated with Pam3CSK4-induced effector T cell resistance to regulatory T cell suppression. J Immunol. 193:5786-90. PMC4258445
James EA, Rieck M, Pieper J, Gebe JA, Yue BB, Tatum M, Peda M, Sandin C, Klareskog L, Malmström V, Buckner JH. (2014) Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol. 66:1712-22. PMC4248674
Mason MJ, Speake C, Gersuk VH, Nguyen QA, O'Brien KK, Odegard JM, Buckner JH, Greenbaum CJ, Chaussabel D, Nepom GT. (2014) Low HERV-K(C4) copy number is associated with type 1 diabetes. Diabetes. 63:1789-95.
Pieper J, Johansson S, Snir O, Linton L, Rieck M, Buckner JH, Winqvist O, van Vollenhoven R, Malmström V. (2014) Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics. Scand J Immunol. 79:149-55. PMC4064710
Long A, Buckner JH. (2013) Intersection between genetic polymorphisms and immune deviation in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 20:285-91.
Young KA, Deane KD, Derber LA, Hughes-Austin JM, Wagner CA, Sokolove J, Weisman MH, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Robinson WH, Holers VM, Norris JM. (2013) Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arthritis Rheum. 65:1995-2004. PMC3729718
Demoruelle MK, Parish MC, Derber LA, Kolfenbach JR, Hughes-Austin JM, Weisman MH, Gilliland W, Edison JD, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Norris JM, Holers VM, Deane KD. (2013) Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum. 65:2243-52. PMC3776020
Dai X, James RG, Habib T, Singh S, Jackson S, Khim S, Moon RT, Liggitt D, Wolf-Yadlin A, Buckner JH, Rawlings DJ. (2013) A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest. 123:2024-36. PMC3638909
Bollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ. (2013) Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes. Clin Exp Immunol. 172:363-74. PMC3638909
Gan RW, Deane KD, Zerbe GO, Demoruelle MK, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Holers VM, Norris JM. (2013) Relationship between air pollution and positivity of RA-related autoantibodies in individuals without established RA: a report on SERA. Ann Rheum Dis 72:2002-5. PMC3818364
Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, Riley JL, Ziegler SF. (2013) Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28. J Immunol. 190:4470-3. PMC4197931
Cerosaletti K, Schneider A, Schwedhelm K, Frank I, Tatum M, Wei S, Whalen E, Greenbaum C, Kita M, Buckner J, Long SA. (2013) Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. PLoS One. 8:e83811. PMC3871703
Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH. (2013) In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med. 5:170ra15.
Stone B, Rieck M, Rawlings CA, Kas A, Shendure J, Jones H, Buckner JH. (2012) Identification of novel HLA class II target epitopes for generation of donor-specific T regulatory cells. Clin Immunol. 145:153-60.
Hughes-Austin JM, Deane KD, Derber LA, Kolfenbach JR, Zerbe GO, Sokolove J, Lahey LJ, Weisman MH, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Robinson WH, Holers VM, Norris JM. (2013) Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann Rheum Dis. 72:901-7. PMC3726193
Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; Diabetes TrialNet and the Immune Tolerance Network. (2012) Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 61:2340-8. PMC3425404
Snir O, Bäcklund J, Boström J, Andersson I, Kihlberg J, Buckner JH, Klareskog L, Holmdahl R, Malmström V. (2012) Multifunctional T cell reactivity with native and glycosylated type II collagen in rheumatoid arthritis. Arthritis Rheum. 64:2482-8. PMC3387353
Habib T, Funk A, Rieck M, Brahmandam A, Dai X, Panigrahi AK, Luning Prak ET, Meyer-Bahlburg A, Sanda S, Greenbaum C, Rawlings DJ, Buckner JH. (2012) Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol. 188:487-96. PMC3670766
Long SA, Rieck M, Tatum M, Bollyky PL, Wu RP, Muller I, Ho JC, Shilling HG, Buckner JH. (2011) Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells. J Immunol. 187:3511-20. PMC3178710
Snir O, Rieck M, Gebe JA, Yue BB, Rawlings CA, Nepom G, Malmström V, Buckner JH. (2011) Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum. 63:2873-83. PMC3174345
Long SA, Cerosaletti K, Wan JY, Ho JC, Tatum M, Wei S, Shilling HG, Buckner JH. (2011) An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun. 12:116-25. PMC3058680
Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C, Buckner JH. (2010) Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes. 59:407-15. PMC2809970
Arechiga AF, Habib T, He Y, Zhang X, Zhang ZY, Funk A, Buckner JH. (2009) Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol. 182:3343-7. PMC2797545
Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH. (2008) The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol. 181:7350-5. PMC2597079
Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH. (2007) Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol. 179:4704-10.
Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. (2005) De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci U S A. 102:4103-8. PMC554797
Buckner JH, Van Landeghen M, Kwok WW, Tsarknaridis L. (2002) Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychondritis. Arthritis Rheum. 46:238-44.
Buckner JH, Wu JJ, Reife RA, Terato K, Eyre DR. (2000) Autoreactivity against matrilin-1 in a patient with relapsing polychondritis. Arthritis Rheum 43:939-43.